Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study

(1) Background: Severe COVID-19 outcomes are associated with cytokine release syndrome, characterized by the release of several immune modulators, including Interleukin-6 (IL-6). Tocilizumab (TCZ) is an IL-6 receptor antagonist used to treat rheumatic arthritis. The study aimed to evaluate the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hafez, Wael, Ziade, Mohamad Azzam, Arya, Arun, Saleh, Husam, Abdelshakor, Mahmoud, Fadl Alla, Osman, Agrawal, Pragati, Ali, Sara, Rao, Srinivasa Raghu, Gupta, Subrata, Abdelli, Ikram, Sebastian, Honeymol, Ali, Mohamed, Gador, Muneir, Al Baha, Ziad, Abdelrahman, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868075/
https://www.ncbi.nlm.nih.gov/pubmed/35203844
http://dx.doi.org/10.3390/antibiotics11020241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868075/
https://www.ncbi.nlm.nih.gov/pubmed/35203844
http://dx.doi.org/10.3390/antibiotics11020241

Ejemplares similares